Press Room

Swiss PharmaCan AG is pleased to announce that Glow LifeTech Corp. has further accelerated its path to commercialization following its successful pilot-scale production and the expansion of MyCell™ cannabis ingredient portfolio with the development of liquid MyCell™ CBN and CBG to address the emerging market demand for rare cannabinoids.

Swiss PharmaCan geht neue Wege in der Forschung und Entwicklung. Mit der Übernahme einer Biotechfirma und der Zusammenarbeit mit Universitäten in Slowenien und Malta sowie dem Bau neuer Labore bringt das Startup-Unternehmen ihre Produkte-Entstehungsprozesse auf eine Stufe, die höchste internationale Standards erfüllt.

Swiss PharmaCan is breaking new ground in research and development. By acquiring a biotech company and collaborating with universities in Slovenia and Malta, as well as building new laboratories, the start-up company is bringing its product development processes to a level that meets the highest international standards.

Swiss PharmaCan unveils its new identity, a celebration of the House’s Swiss legacy that aims to fuse devotion to our Swiss roots with our core values of progress and transformation for the global nutraceutical industry.